Companies argue they’re filling a need created by these miracle weight-loss drugs. But are they offering something of real value — or simply taking advantage of another food fad?

Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...

This valuable study reports on the critical role of ANKRD5 (ANKEF1) in sperm motility and male fertility. However, the supporting data remain incomplete. This work will be of interest to biomedical ...

On The Readout LOUD this week, STAT reporters discuss the FDA's staff cuts, how next-gen drugs may lead to too much weight ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, ...

An eco warrior for your bathroom, just one bar equals three bottles of traditional shampoo or conditioner. Designed for dry ...

Explore Advanced Micro Devices, Inc.'s journey from fabless strategy to AI market challenges, stock-based dilution, and ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...